Integra LifeSciences (NASDAQ:IART) Upgraded at Argus

Argus upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a report issued on Monday morning, Marketbeat reports.

Separately, Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Trading Up 0.8 %

Shares of IART opened at $21.78 on Monday. The firm has a market cap of $1.68 billion, a P/E ratio of -241.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $34.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The business has a 50-day moving average of $23.61 and a 200 day moving average of $22.27.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.89 earnings per share. As a group, research analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the business. Sachem Head Capital Management LP bought a new position in Integra LifeSciences in the 3rd quarter worth about $44,153,000. Paradigm Capital Management Inc. NY grew its holdings in shares of Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after purchasing an additional 901,600 shares in the last quarter. Capital Research Global Investors increased its position in shares of Integra LifeSciences by 7.4% in the fourth quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company’s stock worth $31,765,000 after purchasing an additional 95,944 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after purchasing an additional 618,773 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in Integra LifeSciences during the fourth quarter valued at approximately $28,940,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.